The Second International Consensus Guidelines on the Management of BK Polyomavirus in Kidney Transplantation
Camille N Kotton,Nassim Kamar,David Wojciechowski,Michael Eder,Helmut Hopfer,Parmjeet Randhawa,Martina Sester,Patrizia Comoli,Helio Tedesco Silva,Greg Knoll,Daniel C Brennan,Jennifer Trofe-Clark,Lars Pape,David Axelrod,Bryce Kiberd,Germaine Wong,Hans H Hirsch,Transplantation Society International BK Polyomavirus Consensus Group,Sophie Caillard,Mario Fernandez-Ruiz,Rainer Oberbauer,Ligia Pierrotti,Cinthia Drachenberg,Yael Heher,Gang Huang,Michael Mengel,Luis Morales Buenrostro,Brian Nankivell,Laurie Bertels,Anantharaman Vathsala,Franck Halary,Albert Heim,Deepali Kumar,Karoline Leuzinger,Christine Hanssen Rinaldo,Joanna Schaenman,Monica Slavin,Stefan Schaub,Ilies Benotmane,Nicole Theodoropoulos,Ilkka Helantera,Oliver Witzke,Steven Chadban,Soumita Bagchi,Nissreen Elfadawy,Vikas R Dharnidharka,Motoshi Hattori,Raman Venkataramanan,Burkhard Tönshoff,Benjamin Laskin,Daniel Abramowicz,Marcelo Cantarovich,Marta Crespo,Sanjay Kumar Agarwal,Nicolas Mueller,Ya-Chung Tian
DOI: https://doi.org/10.1097/TP.0000000000004976
2024-09-01
Transplantation
Abstract:BK polyomavirus (BKPyV) remains a significant challenge after kidney transplantation. International experts reviewed current evidence and updated recommendations according to Grading of Recommendations, Assessment, Development, and Evaluations (GRADE). Risk factors for BKPyV-DNAemia and biopsy-proven BKPyV-nephropathy include recipient older age, male sex, donor BKPyV-viruria, BKPyV-seropositive donor/-seronegative recipient, tacrolimus, acute rejection, and higher steroid exposure. To facilitate early intervention with limited allograft damage, all kidney transplant recipients should be screened monthly for plasma BKPyV-DNAemia loads until month 9, then every 3 mo until 2 y posttransplant (3 y for children). In resource-limited settings, urine cytology screening at similar time points can exclude BKPyV-nephropathy, and testing for plasma BKPyV-DNAemia when decoy cells are detectable. For patients with BKPyV-DNAemia loads persisting >1000 copies/mL, or exceeding 10 000 copies/mL (or equivalent), or with biopsy-proven BKPyV-nephropathy, immunosuppression should be reduced according to predefined steps targeting antiproliferative drugs, calcineurin inhibitors, or both. In adults without graft dysfunction, kidney allograft biopsy is not required unless the immunological risk is high. For children with persisting BKPyV-DNAemia, allograft biopsy may be considered even without graft dysfunction. Allograft biopsies should be interpreted in the context of all clinical and laboratory findings, including plasma BKPyV-DNAemia. Immunohistochemistry is preferred for diagnosing biopsy-proven BKPyV-nephropathy. Routine screening using the proposed strategies is cost-effective, improves clinical outcomes and quality of life. Kidney retransplantation subsequent to BKPyV-nephropathy is feasible in otherwise eligible recipients if BKPyV-DNAemia is undetectable; routine graft nephrectomy is not recommended. Current studies do not support the usage of leflunomide, cidofovir, quinolones, or IVIGs. Patients considered for experimental treatments (antivirals, vaccines, neutralizing antibodies, and adoptive T cells) should be enrolled in clinical trials.